nyuuzyou/wikis huggingface dataset:
Edrecolomab (Panorex)

This medication was never approved by the FDA, but was the first monoclonal antibody approved for a cancer indication, in Germany (1995).
==Mechanism of action==
From the NCI Drug Dictionary: A murine monoclonal IgG2a antibody to tumor-associated epithelial cell adhesion molecule (EpCAM, or 17-1A) antigen. Edrecolomab attaches to EpCAM, a human cell surface glycoprotein that is found on normal epithelial cells and some tumor cells, such as those of colon and breast carcinomas. Upon binding, this agent recruits the body's immune effector cells, which may exhibit antitumor cytotoxicity.
==Diseases for which it was used==
*Colon cancer
==Also known as==
*Brand name: Panorex
Category:Drugs
Category:Intravenous medications
Category:Anti-EpCAM antibodies
Category:Colon cancer medications (historic)
Category:EMA approved in 1995
Category:Discontinued drugs
Efanesoctocog alfa (Altuviiio)

==Mechanism of action==
From Wikipedia: Efanesoctocog alfa is a recombinant DNA-derived, Factor VIII concentrate.
==Diseases for which it is used==
*Congenital hemophilia A
==History of changes in FDA indication==
*2023-02-22: Initial approval for use in adults and children with Hemophilia A (congenital Factor VIII deficiency) for: (1) Routine prophylaxis to reduce the frequency of bleeding episodes; (2) On-demand treatment and control of bleeding episodes; and (3) Perioperative management of bleeding. (Based on XTEND-1)
*2024-05-10: Approval updated to include additional evidence. (Based on XTEND-Kids)
==Also known as==
*Code name: BIVV-001
*Brand name: Altuviiio
Category:Drugs
Category:Inherited coagulopathy medications
Category:Recombinant medications
Category:Hematology medications
Category:Hemostasis medications
Category:Coagulation factors
Category:FDA approved in 2023
Eflornithine (Iwilfin)

==Mechanism of action==
From the NCI Drug Dictionary: A difluoromethylated ornithine compound with antineoplastic activity. Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells.
==Diseases for which it is used==
*Neuroblastoma
==History of changes in FDA indication==
*2023-12-13: Approved to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. (Based on NMTRC003B)
==Also known as==
*Code names: MDL-71782, RMI-71782
*Generic names: DFMO, difluoromethylornithine
*Brand names: Iwilfin, Ornidyl
Category:Drugs
Category:Intravenous medications
Category:Ornithine decarboxylase inhibitors
Category:Neuroblastoma medications
Category:FDA approved in 2023
Elacestrant (Orserdu)

==Mechanism of action==
From the NCI Drug Dictionary: An orally available, selective estrogen receptor degrader (SERD) and selective estrogen receptor modulator (SERM), with potential antineoplastic and estrogen-like activities. Upon oral administration of higher doses of elacestrant, this agent acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells. At lower doses of this agent, RAD1901 acts as a SERM and has estrogen-like effects in certain tissues, which can both reduce hot flashes and protect against bone loss. In addition, elacestrant is able to cross the blood-brain barrier (BBB).
==Diseases for which it is established==
*Breast cancer, ER-positive
==History of changes in FDA indication==
*2023-01-27: Approved for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. (Based on EMERALD)
==History of changes in EMA indication==
*2023-09-20: Initial marketing authorization as Orserdu. Orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.
==Also known as==
*Code name: RAD-1901
*Brand name: Orserdu
Category:Drugs
Category:Intramuscular medications
Category:Mutation-specific medications
Category:Estrogen receptor inhibitors
Category:Breast cancer medications
Category:FDA approved in 2023
Category:EMA approved in 2023
Elotuzumab (Empliciti)

==General information==
Class/mechanism: Humanized IgG1 monoclonal antibody which targets SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7). SLAMF7 is a protein which is expressed on myeloma cells, Natural Killer cells, plasma cells, and expressed at lower levels on certain immune cell subsets of differentiated cells. Elotuzumab facilitates antibody-dependent cellular cytotoxicity (ADCC) between myeloma cells and Natural Killer cells. The antigen target of elotuzumab may also be known as CS1 (CD2 subset 1, CRACC, SLAMF7).Elotuzumab (Empliciti) package insertElotuzumab (Empliciti) package insert (locally hosted backup)Empliciti manufacturer's websiteElotuzumab entry at the NCI Drug Dictionary
Elotuzumab (HuLuc63) @ the Multiple Myeloma Research Foundation
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, or the package insert.
==Diseases for which it is established==
*Multiple myeloma
==Patient drug information==
*Elotuzumab (Empliciti) package insert
==History of changes in FDA indication==
*2015-11-30: FDA approved to be used in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. (Based on ELOQUENT-2)
*2018-11-06: Approved in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. (Based on ELOQUENT-3)
==History of changes in EMA indication==
*2016-05-11: Initial authorization
==History of changes in Health Canada indication==
*2016-06-21: Initial notice of compliance
==History of changes in PMDA indication==
*2016-09-28: New approval for the treatment of relapsed or refractory multiple myeloma.
==Also known as==
*Code names: BMS-901608, HuLuc63, PDL-063
*Generic name: anti-CS1 monoclonal antibody HuLuc63
*Brand name: Empliciti
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-SLAMF7 antibodies
Category:Multiple myeloma medications
Category:FDA approved in 2015
Category:EMA approved in 2016
Category:Health Canada approved in 2016
Category:PMDA approved in 2016
Elranatamab (Elrexfio)

==General information==
Class/mechanism from the NCI Drug Dictionary: A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab binds to both CD3 on T cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells.
Route: IV
Extravasation: no information
==Toxicity management==
*REMS information (FDA hosted)
==Diseases for which it is established==
*Multiple myeloma
==History of changes in FDA indication==
*2023-08-14: Granted accelerated approval for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (Based on MagnetisMM-3)
==History of changes in EMA indication==
*2023-10-12: CHMP recommends conditional marketing authorisation as Elrexfio. Elrexfio is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
==Also known as==
*Code names: PF-06863135, RN-613
*Generic name: elranatamab-bcmm
*Brand name: Elrexfio
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-BCMA-CD3 bispecific antibodies
Category:Multiple myeloma medications
Category:REMS program
Category:FDA approved in 2023
Category:Pfizer product
Eltrombopag (Promacta)

==General information==
Class/mechanism: Thrombopoietin (TPO) receptor agonist; interacts with the transmembrane domain of the TPO-receptor to trigger downstream signal cascades that ultimately stimulate platelet production by promoting proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.Eltrombopag (Promacta) package insert Eltrombopag (Promacta) package insert (locally hosted backup)Promacta manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*Aplastic anemia
*Immune thrombocytopenia
==Patient drug information==
*Eltrombopag (Promacta) package insert 
*Eltrombopag (Promacta) patient drug information (UpToDate)Eltrombopag (Promacta) patient drug information (UpToDate)
==History of changes in FDA indication==
* 2008-11-20: Initial approval for treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
* 2012-11-19: Approved for treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. (Non-hematologic indication)
* 2014-08-26: Approved for patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
* 2015-08-24: Approved for the treatment of thrombocytopenia in pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
==History of changes in EMA indication==
*2010-03-11: Initial authorization as Revolade
==History of changes in PMDA indication==
*2017-08-25: New additional indication and a new dosage for the treatment of aplastic anemia.
==Also known as==
*Code name: SB-497115-GR
*Generic name: eltrombopag olamine
*Brand names: Eltrom, Promacta, Revolade
==References==
Category:Drugs
Category:Oral medications
Category:Hematopoietic growth factors
Category:Megakaryocyte growth factors
Category:Aplastic anemia medications
Category:Immune thrombocytopenia medications
Category:FDA approved in 2008
Category:EMA approved in 2010
Emapalumab (Gamifant)

==General information==
Class/mechanism from the NCI Drug Dictionary: A human monoclonal antibody against the cytokine interferon-gamma (IFN-gamma; IFNg), with potential immunomodulating activity. Upon administration, emapalumab binds to and neutralizes IFNg. This inhibits IFNg-mediated signaling pathways and suppresses the activation of the immune system.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*Hemophagocytic lymphohistiocytosis
==History of changes in FDA indication==
* 2018-11-20: Initial approval for adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. (Based on NI-0501-04)
== Patient Drug Information==
*Emapalumab (Gamifant) Package InsertEmapalumab (Gamifant) Package Insert
==Also known as==
*Code name: NI-0501
*Generic name: emapalumab-lzsg
*Brand name: Gamifant
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-IFNg antibodies
Category:Hemophagocytic lymphohistiocytosis medications
Category:FDA approved in 2018
Emicizumab (Hemlibra)

==Mechanism of action==
A recombinant, humanized, bispecific monoclonal antibody that bridges activated factor IX and factor X to restore the function of missing activated factor VIII.
==Diseases for which it is used==
*Acquired factor VIII inhibitor in the setting of inherited factor VIII deficiency
*Acquired hemophilia A
==History of changes in FDA indication==
*2017-11-16: Approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.
*2018-10-04: Approval expanded for prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (ages newborn and older) with hemophilia A (congenital factor VIII deficiency) with or without factor VIII (FVIII) inhibitors. (requirement for inhibitor to be present was removed)
==History of changes in EMA indication==
*2018-02-23: Initial authorisation
*Uncertain date: Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors. Hemlibra can be used in all age groups.
*2023-03-06: Indicated revised to include patients with haemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors who have severe disease (FVIII < 1%) or moderate disease (FVIII at least 1% and up to 5%) with severe bleeding phenotype. Hemlibra can be used in all age groups.
==History of changes in PMDA indication==
*2022-06-20: Drugs with a new indication and a new dosage for the control of bleeding tendency in patients with acquired hemophilia A.
=Also known as=
*Code name: ACE-910
*Generic name: emicizumab-kxwh
*Brand name: Hemlibra
Category:Drugs
Category:Subcutaneous medications
Category:Anti-Factor IXa-Factor Xa bispecific antibodies
Category:Inherited coagulopathy medications
Category:FDA approved in 2017
Category:EMA approved in 2018
Enasidenib (Idhifa)

==Mechanism of action==
From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).Enasidenib (Idhifa) package insert
==Diseases for which it is used==
*Acute myeloid leukemia, IDH-mutated
==History of changes in FDA indication==
*2017-08-01: Granted FDA regular approval for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. (Based on AG-221-C-001 relapsed)
==History of changes in Health Canada indication==
*2019-02-06: Initial notice of compliance with conditions for the treatment of adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) with an isocitrate dehydrogenase-2 IDH2 mutation.
==Patient Drug Information==
*Enasidenib (Idhifa) Package Insert
==Also known as==
*Code names: AG-221, CC-90007
*Generic name: enasidenib mesylate
*Brand name: Idhifa
==References==
Category:Drugs
Category:Oral medications
Category:Mutation-specific medications
Category:Acute myeloid leukemia medications
Category:IDH2 inhibitors
Category:FDA approved in 2017
Category:Health Canada approved in 2019
Encorafenib (Braftovi)

==General information==
Class/mechanism (from NCI Drug Dictionary): An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway.
==Diseases for which it is established==
*BRAF-mutated CRC
*BRAF-mutated melanoma
*BRAF-mutated NSCLC
==History of changes in FDA indication==
*2018-06-27: Initial approval in combination with Binimetinib (Mektovi) for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Based on COLUMBUS)
*2020-04-09: Approved in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, detected by an FDA-approved test, after prior therapy. (Based on BEACON CRC)
*2023-10-11: Approved with Binimetinib (Mektovi) for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. (Based on PHAROS)
*2024-12-20: Granted accelerated approval with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. (Based on BREAKWATER)
==History of changes in EMA indication==
*2018-09-19: Iniital authorization
==History of changes in Health Canada indication==
*2021-03-02: Initial notice of compliance for use in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.
==History of changes in PMDA indication==
*2019-01-08: New approval for the treatment of unresectable melanoma with BRAF gene mutation.
*2020-11-27: New indication and a new dosage for the treatment of unresectable, advanced or recurrent BRAF mutation-positive colorectal cancer that has progressed after cancer chemotherapy.
==Also known as==
*Code name: LGX-818
*Brand name: Braftovi
Category:Drugs
Category:Oral medications
Category:Mutation-specific medications
Category:BRAF inhibitors
Category:Colorectal cancer medications
Category:Melanoma medications
Category:Non-small cell lung cancer medications
Category:EMA approved in 2018
Category:FDA approved in 2018
Category:Health Canada approved in 2021
Category:PMDA approved in 2019
Endocrine ablation surgery

One of a limited number of procedures intended to remove endocrine exposure and thus indirectly exert an antineoplastic effect. This page is currently a placeholder meant to enable accurate creation of the HemOnc.org ontology.
=Bilateral adrenalectomy=
=Bilateral oophorectomy=
=Bilateral orchiectomy=
=Ovarian irradiation=
Category:Antiandrogens
Category:Antiestrogens
Endometrial cancer - historical

Back to Top
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main endometrial cancer page for current regimens.
Last updated on 2024-12-02:1 regimens on this page
1 variants on this page
 
=Adjuvant therapy=
==Whole abdominal radiation (WAI)==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Randall et al. 2006 (GOG 122)	1992-2000 	Phase 3 (E-switch-ooc)	Cisplatin & Doxorubicin	Shorter OS (secondary endpoint)
Wolfson et al. 2007 (GOG 150)	1993-2005 	Phase 3 (C) 	CIM 	Might have shorter OSMedian OS: 24 vs 48 mo(HR 1.41, 95% CI 0.95-2.08)
Not commonly used but was a comparator arm.
====Radiotherapy====
*External beam radiotherapy
One course
===References===
# GOG 122: Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA; Gynecologic Oncology Group. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2006 Jan 1;24(1):36-44. Epub 2005 Dec 5. link to original article EuroPMC
# GOG 150: Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, Cohn DE, Ioffe OB. A Gynecologic Oncology Group randomized phase III trial of whole abdominal irradiation (WAI) vs cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007 Nov;107(2):177-85. Epub 2007 Sep 5. link to original article link to PMC article EuroPMC NCT00002546
Category:Endometrial cancer regimens
Category:Historical regimens
Category:Disease-specific pages
Category:Gynecologic cancers
Enoxaparin (Lovenox)

==General information==
Class/mechanism: Low molecular weight heparin, binds to antithrombin III, accelerating its activity and inhibiting factor Xa and thrombin.Enoxaparin (Lovenox) package insert Enoxaparin (Lovenox) package insert (locally hosted backup)Lovenox manufacturer's website
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Patient drug information==
*Brief patient counseling information can be found on page 10 of the package insert
*Enoxaparin (Lovenox) patient drug information (UpToDate)Enoxaparin (Lovenox) patient drug information (UpToDate)
==History of changes in FDA indication==
*1993-03-29: Initial FDA approval: prevention of DVT following hip replacement
==Also known as==
*Brand names: Axoparin, Cardinex, Clexan, Clexane, Clotinex, Cnoxane, Cutenox, Dutenox, Enclex, Enox, Enxoaealth, Enoxol, Eparin, Lmwx, Lovenox, Markparin, Microparin, Noxprin, Pariparin, Xaparin
==References==
Category:Drugs
Category:Subcutaneous medications
Category:Anticoagulants
Category:Heparins
Category:Low molecular weight heparins
Category:Venous thromboembolism medications
Category:FDA approved in 1993